Cardiometabolic Effects of Denosumab in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression: RCT
Details
Publication Year 2024-09-16,Volume 109,Issue #10,Page e1857-e1866
Journal Title
Journal of Clinical Endocrinology and Metabolism
Publication Type
Research article
Abstract
CONTEXT: Menopause is associated with changes in musculoskeletal, body composition, and metabolic parameters that may be amplified in premenopausal women receiving estradiol suppression for breast cancer. Denosumab offsets deleterious skeletal effects of estradiol suppression and has been reported to have effects on body composition and metabolic parameters in preclinical and observational studies, but evidence from double-blind randomized controlled trials is limited. OBJECTIVE: To assess the effect of denosumab on body composition and metabolic parameters. METHODS: In a prespecified secondary analysis of a 12-month randomized, double-blind, placebo-controlled trial, 68 premenopausal women with breast cancer initiating ovarian function suppression and aromatase inhibition were randomized to denosumab 60-mg or placebo administered at baseline and 6 months. Outcome measures were total and regional fat and lean mass (DXA), body mass index (BMI), waist and hip circumference, fasting glucose, HOMA-IR, and lipid profile. Using a mixed model, between-group mean adjusted differences over time are reported. RESULTS: Over 12 months, relative to placebo, android and gynoid fat mass decreased in the denosumab group (-266 g [95% CI -453 to -79], P = .02, and -452 g [-783 to -122], P = .03, respectively). Total fat mass and waist circumference were lower in the denosumab group but not significantly (-1792 g [-3346 to -240], P = .08 and (- 3.77 cm [-6.76 to -0.79], P = .06, respectively). No significant treatment effects were detected in lean mass, BMI, hip circumference, fasting glucose, HOMA-IR, or lipid profile. CONCLUSION: In premenopausal women receiving estradiol suppression, denosumab decreases some measures of fat mass with no detectable effects on other measures of body composition or metabolic parameters.
Publisher
Oxford University Press
Keywords
Humans; Female; *Denosumab/therapeutic use; *Breast Neoplasms/drug therapy/pathology; *Premenopause; Adult; Double-Blind Method; *Estradiol/blood; *Body Composition/drug effects; Middle Aged; Body Mass Index; Aromatase Inhibitors/therapeutic use/adverse effects; Bone Density Conservation Agents/therapeutic use; body composition; breast cancer; denosumab; estradiol suppression; glucose metabolism; lipids
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1210/clinem/dgae003
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-10-01 07:37:01
Last Modified: 2024-10-01 07:37:20

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙